Rubin Lab

RECENT LAB PUBLICATIONS

Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.

Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tuan Tiong JH, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R, International Organization for Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022. In Press. PMID: 35487235.

HTML

 

What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?​.

Krugliak Cleveland N, Torres J, Rubin DT. Gastroenterology. 2022;162(5):1396-1408. PMID: 35101421.

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study.

Sandborn WJ, D’Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG, GALAXI-1 Investigators. Gastroenterology. 2022;162(6):1650-1664. PMID: 35134323.

The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease.

Anyane-Yeboa A, Quezada S, Rubin DT, Balzora S. Clin Gastroenterol Hepatol. 2022. In Press. PMID: 35307597.

Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis​.

Mikolajczyk AE,Cohen N, Watson S, Ackerman M, Goeppinger SR, Hart J, Turner JR, Rubin DT. Inflamm Bowel Dis. 2022. [Epub ahead of print April 18 2022]. PMID: 35436339.

Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey​.

Parigi TL, D’Amico F, Abreu MT, Dignass A, Dotan I, Jairath V, Magro F, Rubin DT, Peyrin-Biroulet L, Ghosh S, Danese S. Lancet Gastroenterol Hepatol. 2022;7(5):390-391. PMID: 35397241.

IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus​.

Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O’Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L. Clin Gastroenterol Hepatol. 2022. [Epub ahead of print February 19 2022]. PMID: 35189386.

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD​.

Click B, Barnes EL, Cohen BL, Sands BE, Hanson JS, Rubin DT, Dubinsky MC, Regueiro M, Gazis D, Crawford JM, Long MD. BMC Gastroenterol. 2022. [Epub ahead of print February 19 2022]. PMID: 35183108.

Self-Reported Failure to Address Sexual Function in Patients with Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement.

Christensen B, Prentice RE, Al-Ani AH, Zhang E, Bedell A, Rubin DT. Inflamm Bowel Dis. 2022. [Epub ahead of print March 14 2022]. PMID: 35286382.

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases​.

Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O’Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. Lancet Gastroenterol Hepatol. 2022;7(3):254-261. PMID: 35051383.